ProShares Ultra Nasdaq Biotechnology (BIB) closed at $116.13 on November 13, 2026, down 1.1% from the previous close, on volume of 5,033 shares (30-day average 8,798).
Data as of November 13, 2026.
13-Nov-2026
No press releases found.
Halozyme downgraded at Morgan Stanley on valuation
Seeking Alpha News (Wed, 11-Nov 12:09 PM ET)
ProShares Ultra Nasdaq Biotechnology seeks daily investment results before fees and expenses that correspond to twice (200%) the daily performance of the NASDAQ Biotechnology Index.
ProShares Ultra Nasdaq Biotechnology trades on the NASDAQ stock market under the symbol BIB.
As of November 13, 2026, BIB stock price declined to $116.13 with 5,033 million shares trading.
BIB has a market cap of $102.19 million. This is considered a Micro Cap stock.
In the last 3 years, BIB traded as high as $126.40 and as low as $33.78.
BIB has outperformed the market in the last year with a return of +53.0%, while the SPY ETF gained +11.5%. In the last 3 month period, BIB beat the market returning +6.2%, while SPY returned -2.1%. However, in the most recent 2 weeks BIB has underperformed the stock market by returning -3.7%, while SPY returned -1.9%.
BIB support price is $112.83 and resistance is $121.98 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that BIB shares will trade within this expected range on the day.
